Meredith Angel, MD
Urology · Campbellsville, KYNPI 1053724278
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (53.5%), food and beverage and education — rather than concentrated in one kind of arrangement. Angiodynamics, Inc. accounts for 60.1% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $4,514, more than ten times the $392 reported in 2019.
Across 143 payments — averaging $44.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$4K
- Astellas Pharma US Inc$781
- Pfizer$231
- Johnson & Johnson$172
- C. R. Bard, Inc. & Subsidiaries$147
- Sumitomo Pharma America, Inc.$136
- plus $1K from 24 others
Across 1 payment — averaging $24,106 each. An ownership or investment interest held by the physician or an immediate family member.
- Green River URS Consumables, LLC$24K
What the payments were for
- Travel & lodging$3245%
- Food & beverage$2,20635%
- Education$4347%
- Other$3,41754%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 12 | $3,833 |
| Astellas Pharma US Inc | 33 | $781 |
| Pfizer | 12 | $231 |
| Johnson & Johnson | 11 | $172 |
| C. R. Bard, Inc. & Subsidiaries | 13 | $147 |
| Sumitomo Pharma America, Inc. | 7 | $136 |
| Procept Biorobotics Corporation | 2 | $111 |
| 180 Medical, Inc. | 5 | $109 |
| Axonics, Inc. | 7 | $97 |
| AbbVie(2 entities) | 4 | $96 |
| Bayer | 6 | $75 |
| Endo USA, Inc. | 3 | $66 |
| Accord Healthcare, Inc. | 4 | $63 |
| Olympus America Inc. | 2 | $50 |
| Convatec Inc. | 2 | $43 |
| Urogen Pharma, Inc. | 2 | $41 |
| Boston Scientific | 3 | $39 |
| Photocure Inc | 2 | $35 |
| AstraZeneca | 1 | $35 |
| Tempus AI, Inc | 1 | $29 |
| Laborie Medical Technologies Corp. | 1 | $28 |
| Pacira Pharmaceuticals Incorporated | 2 | $27 |
| Tolmar, Inc. | 1 | $23 |
| Conmed Corporation | 1 | $19 |
| Neotract Inc. | 1 | $18 |
| Telix Pharmaceuticals | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
| Amgen | 1 | $14 |
| Dentsply IH Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nanoknife$3,734
How this compares
$6,381 in reported general payments places this provider in the 70th percentile of 139 urology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 90 | $48,144 |
| GemtesaVibegron | 17 | $9,643 |
| Methenamine Hippurate | 98 | $5,895 |
| Mirabegron ErMirabegron | 12 | $5,479 |
| Estradiol | 41 | $2,965 |
| Tamsulosin Hcl | 340 | $2,243 |
| Fosfomycin Tromethamine | 11 | $2,166 |
| Potassium Citrate ErPotassium Citrate | 40 | $2,029 |
| Trospium Chloride ErTrospium Chloride | 14 | $1,740 |
| Finasteride | 185 | $1,735 |
| Trospium Chloride | 47 | $1,502 |
| Oxybutynin Chloride ErOxybutynin Chloride | 156 | $1,404 |
| Silodosin | 19 | $1,148 |
| Cefdinir | 69 | $983 |
| Gentamicin Sulfate | 12 | $835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $781 | $48,14490 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $136 | $9,64317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 139 urology providers in Kentucky.
Other urology in Campbellsville
- Thomas SlabaughLexington$102K
- Uzoma AneleLouisville$60K
- Lee EvansHopkinsville$56K
- Patrick HensleyLexington$50K
- Brooke EdwardsCrestview Hills$45K
- Robert LarkeCrestview Hills$22K
- Stephen MonnigLexington$18K
- Kellen ChoiLouisville$17K
- Rosa ParkLouisville$16K
- Brian ShayCrestview Hills$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.